

Lã;szlã³ Muszbek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4214841/publications.pdf>

Version: 2024-02-01

218
papers

6,327
citations

76196

40
h-index

91712

69
g-index

221
all docs

221
docs citations

221
times ranked

4006
citing authors

#	ARTICLE	IF	CITATIONS
1	Factor XIII: A Coagulation Factor With Multiple Plasmatic and Cellular Functions. <i>Physiological Reviews</i> , 2011, 91, 931-972.	13.1	384
2	Blood Coagulation Factor XIII. <i>Thrombosis Research</i> , 1999, 94, 271-305.	0.8	288
3	Factor XIII Deficiency. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 426-438.	1.5	197
4	Novel Aspects of Blood Coagulation Factor XIII. I. Structure, Distribution, Activation, and Function. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1996, 33, 357-421.	2.7	182
5	Diagnosis and classification of factor XIII deficiencies. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1404-1406.	1.9	157
6	Factor XIII: novel structural and functional aspects. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 9-20.	1.9	146
7	Factor XIII of blood coagulation in human monocytes. <i>Thrombosis Research</i> , 1985, 37, 401-410.	0.8	130
8	Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. <i>Journal of Rheumatology</i> , 2008, 35, 398-406.	1.0	130
9	International Registry on Factor XIII Deficiency: A basis formed mostly on European data. <i>Thrombosis and Haemostasis</i> , 2007, 97, 914-921.	1.8	129
10	A highly sensitive method for the measurement of ATPase activity. <i>Analytical Biochemistry</i> , 1977, 77, 286-288.	1.1	110
11	The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2008, 6, 190-205.	0.4	110
12	Factor XIII, clot structure, thrombosis. <i>Thrombosis Research</i> , 2012, 129, 382-387.	0.8	107
13	Impaired wound healing in factor XIII deficient mice. <i>Thrombosis and Haemostasis</i> , 2005, 94, 432-7.	1.8	102
14	Effect of Val34Leu Polymorphism on the Activation of the Coagulation Factor XIII-A. <i>Thrombosis and Haemostasis</i> , 2000, 84, 595-600.	1.8	92
15	Coagulation Factor Deficiencies and Pregnancy Loss. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 171-174.	1.5	92
16	Covalent binding of arachidonate to G protein alpha subunits of human platelets. <i>Journal of Biological Chemistry</i> , 1994, 269, 4713-6.	1.6	91
17	A Simple, Quick One-step ELISA Assay for the Determination of Complex Plasma Factor XIII (A2B2). <i>Thrombosis and Haemostasis</i> , 2000, 83, 268-273.	1.8	88
18	Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). <i>Biochemical Journal</i> , 1990, 267, 557-560.	1.7	76

#	ARTICLE	IF	CITATIONS
19	ETRO Working Party on Factor XIII Questionnaire on Congenital Factor XIII Deficiency in Europe: Status and Perspectives. <i>Seminars in Thrombosis and Hemostasis</i> , 1996, 22, 415-418.	1.5	70
20	Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. <i>Blood</i> , 2009, 113, 723-725.	0.6	69
21	Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. <i>Journal of Immunological Methods</i> , 2001, 258, 127-135.	0.6	67
22	Novel aspects of factor XIII deficiency. <i>Current Opinion in Hematology</i> , 2011, 18, 366-372.	1.2	67
23	Identification of histiocytic reticulum cells by the immunohistochemical demonstration of factor XIII (F-XIIIa) in human lymph nodes. <i>Journal of Pathology</i> , 1986, 149, 121-132.	2.1	66
24	Characterisation of connective tissue cells containing factor XIII subunit a.. <i>Journal of Clinical Pathology</i> , 1988, 41, 49-56.	1.0	66
25	Diagnosis and Management of Congenital and Acquired FXIII Deficiencies. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 429-439.	1.5	66
26	Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients. <i>Lupus</i> , 2003, 12, 302-307.	0.8	61
27	Transglutaminase-sensitive glutamine residues of human plasma fibronectin revealed by studying its proteolytic fragments. <i>FEBS Journal</i> , 1986, 154, 371-374.	0.2	60
28	Platelet Factor XIII Becomes Active without the Release of Activation Peptide during Platelet Activation. <i>Thrombosis and Haemostasis</i> , 1993, 69, 282-285.	1.8	58
29	Factor XIII: a marker of mono- and megakaryocytopoiesis. <i>British Journal of Haematology</i> , 1987, 67, 167-172.	1.2	56
30	Possible role of factor XIII subunit A in Fc γ 3 and complement receptor-mediated phagocytosis. <i>Cellular Immunology</i> , 2004, 228, 81-90.	1.4	56
31	Interaction of factor XIII subunits. <i>Blood</i> , 2014, 123, 1757-1763.	0.6	55
32	Kinetic determination of blood coagulation Factor XIII in plasma.. <i>Clinical Chemistry</i> , 1985, 31, 35-40.	1.5	53
33	Comparison of PFA-100 Closure Time and Template Bleeding Time of Patients with Inherited Disorders Causing Defective Platelet Function. <i>Thrombosis Research</i> , 1999, 96, 487-492.	0.8	52
34	Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations. <i>Journal of Molecular Graphics and Modelling</i> , 2013, 40, 99-109.	1.3	48
35	Identification of blood coagulation factor XIII in human peritoneal macrophages. <i>European Journal of Cell Biology</i> , 1985, 38, 171-3.	1.6	47
36	Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. <i>Human Mutation</i> , 2004, 23, 98-98.	1.1	45

#	ARTICLE	IF	CITATIONS
37	P-selectin is acylated with palmitic acid and stearic acid at cysteine 766 through a thioester linkage. <i>Journal of Biological Chemistry</i> , 1993, 268, 11394-400.	1.6	45
38	Molecular Mechanism of a Mild Phenotype in Coagulation Factor XIII (FXIII) Deficiency: A Splicing Mutation Permitting Partial Correct Splicing of FXIII A-Subunit mRNA. <i>Blood</i> , 1997, 89, 1279-1287.	0.6	44
39	Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2075-2077.	1.9	43
40	4-Thio-deoxyuridylate-modified thrombin aptamer and its inhibitory effect on fibrin clot formation, platelet aggregation and thrombus growth on subendothelial matrix. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1764-1771.	1.9	43
41	Factor XIII and inflammatory cells. <i>Thrombosis Research</i> , 2012, 129, S77-S81.	0.8	42
42	Characterization of factor XIII containing-macrophages in lymph nodes with Hodgkin's disease. <i>British Journal of Cancer</i> , 1987, 55, 421-426.	2.9	40
43	Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. <i>Thrombosis Research</i> , 2007, 120, 567-573.	0.8	40
44	Factor XIII Val34Leu variant protects against coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2007, 97, 458-463.	1.8	40
45	Factor XIII: recommended terms and abbreviations1. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 181-183.	1.9	39
46	Glycoprotein Ib and glycoprotein IX in human platelets are acylated with palmitic acid through thioester linkages. <i>Journal of Biological Chemistry</i> , 1989, 264, 9716-9.	1.6	39
47	Covalent modification of proteins by arachidonate and eicosapentaenoate in platelets. <i>Journal of Biological Chemistry</i> , 1993, 268, 18243-8.	1.6	39
48	Founder effect is responsible for the p.Leu131Phe heparin-binding site antithrombin mutation common in Hungary: phenotype analysis in a large cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 704-715.	1.9	38
49	Transformation of Cellular Factor XIII into an Active Zymogen Transglutaminase in Thrombin-Stimulated Platelets. <i>Thrombosis and Haemostasis</i> , 1995, 73, 702-705.	1.8	37
50	Deficiency Causing Mutations and Common Polymorphisms in the Factor XIII-A Gene. <i>Thrombosis and Haemostasis</i> , 2000, 84, 524-527.	1.8	36
51	Factor XIII and Atherothrombotic Diseases. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 018-033.	1.5	36
52	Severe coagulation factor V deficiency caused by 2 novel frameshift mutations: 2952delT in exon 13 and 5493insG in exon 16 of factor 5 gene. <i>Blood</i> , 2002, 99, 702-705.	0.6	34
53	Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 943-949.	1.9	34
54	Elevated factor XIII level and the risk of myocardial infarction in women. <i>Haematologica</i> , 2007, 92, 287-288.	1.7	34

#	ARTICLE	IF	CITATIONS
55	Factor XIII and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 305-314.	1.5	34
56	Minimal factor XIII activity level to prevent major spontaneous bleeds. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1728-1736.	1.9	34
57	Characterization of rapidly adhering amniotic fluid cells by combined immunofluorescence and phagocytosis assays. <i>American Journal of Human Genetics</i> , 1989, 45, 786-92.	2.6	34
58	The fragmentation of actin by thrombin. Isolation and characterization of the split products. <i>Archives of Biochemistry and Biophysics</i> , 1975, 167, 99-103.	1.4	33
59	Measurement of factor XIII activity in plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1191-1202.	1.4	33
60	International registry on factor XIII deficiency: a basis formed mostly on European data. <i>Thrombosis and Haemostasis</i> , 2007, 97, 914-21.	1.8	33
61	Calcium Binding of Transglutaminases: A ⁴³ Ca NMR Study Combined with Surface Polarity Analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2001, 19, 59-74.	2.0	32
62	Promotion of the Crosslinking of Fibrin and α_2 -antiplasmin by Platelets. <i>Thrombosis and Haemostasis</i> , 1996, 75, 161-167.	1.8	31
63	Cleavage of Actin by Thrombin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1974, 71, 2208-2211.	3.3	30
64	Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. <i>Thrombosis and Haemostasis</i> , 2000, 84, 595-600.	1.8	30
65	Platelet vinculin: a substrate of activated Factor XIII. <i>BBA - Proteins and Proteomics</i> , 1988, 954, 303-308.	2.1	29
66	GJB2 mutations in patients with non-syndromic hearing loss from Northeastern Hungary. <i>Human Mutation</i> , 2004, 23, 631-632.	1.1	29
67	Antithrombin deficiency and its laboratory diagnosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, S67-78.	1.4	29
68	Covalent modification of platelet proteins by palmitate. <i>Blood</i> , 1989, 74, 1339-1347.	0.6	27
69	Myristoylation of proteins in platelets occurs predominantly through thioester linkages. <i>Journal of Biological Chemistry</i> , 1993, 268, 8251-5.	1.6	27
70	Troponin C like protein of blood platelets. <i>FEBS Letters</i> , 1977, 80, 308-312.	1.3	26
71	Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot. <i>Thrombosis and Haemostasis</i> , 2007, 98, 359-367.	1.8	26
72	The Superiority of Anti-FXa Assay Over Anti-FIIa Assay in Detecting Heparin-Binding Site Antithrombin Deficiency. <i>American Journal of Clinical Pathology</i> , 2013, 140, 675-679.	0.4	26

#	ARTICLE	IF	CITATIONS
73	Rapid detection of the factor XIII Val34Leu (163 Gâ†T) polymorphism by real-time PCR using fluorescence resonance energy transfer detection and melting curve analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 877-9.	1.4	25
74	Platelets but not monocytes contribute to the plasma levels of factor XIII subunit A in patients undergoing autologous peripheral blood stem cell transplantation. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 249-253.	0.5	25
75	The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2006, 1764, 1420-1423.	1.1	25
76	New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. <i>Thrombosis Research</i> , 2013, 131, 320-324.	0.8	25
77	Coincidence of mutations in different connexin genes in Hungarian patients. <i>International Journal of Molecular Medicine</i> , 2007, 20, 315-21.	1.8	25
78	Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A. <i>Thrombosis and Haemostasis</i> , 2006, 96, 176-182.	1.8	24
79	Elevated factor XIII level and the risk of peripheral artery disease. <i>Haematologica</i> , 2008, 93, 1430-1432.	1.7	24
80	Protein cross-linking by chlorinated polyamines and transglutamylation stabilizes neutrophil extracellular traps. <i>Cell Death and Disease</i> , 2016, 7, e2332-e2332.	2.7	24
81	Molecular Mechanisms of Mutations in Factor XIII A-subunit Deficiency: In vitro Expression in COS-cells Demonstrates Intracellular Degradation of the Mutant Proteins. <i>Thrombosis and Haemostasis</i> , 1997, 77, 1068-1072.	1.8	24
82	Binding of plasma factor XIII to thrombin-receptor activated human platelets. <i>Thrombosis and Haemostasis</i> , 2009, 102, 83-89.	1.8	23
83	Monocytes of Patients Congenitally Deficient in Plasma Factor XIII Lack Factor XIII Subunit A Antigen and Transglutaminase Activity. <i>Thrombosis and Haemostasis</i> , 1988, 59, 231-235.	1.8	23
84	Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. <i>Blood</i> , 2000, 96, 2479-86.	0.6	23
85	Immunohistochemical detection of factor XIII subunit a in histiocytes of human uterus. <i>Histochemistry</i> , 1989, 91, 169-174.	1.9	22
86	Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias. <i>Thrombosis and Haemostasis</i> , 2005, 94, 454-9.	1.8	22
87	Identification and isolation of vinculin from platelets. <i>FEBS Letters</i> , 1984, 165, 26-30.	1.3	21
88	Interaction between homocysteine and lipoprotein(a) increases the prevalence of coronary artery disease/myocardial infarction in women: A case-control study. <i>Thrombosis Research</i> , 2012, 129, 133-138.	0.8	21
89	Translocation of pp60c-src to the cytoskeleton during platelet aggregation. <i>EMBO Journal</i> , 1992, 11, 855-61.	3.5	21
90	Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit. <i>Thrombosis and Haemostasis</i> , 2008, 99, 668-674.	1.8	20

#	ARTICLE	IF	CITATIONS
91	High Prevalence of Factor V Leiden Mutation and 20210A Prothrombin Variant in Hungary. <i>Thrombosis and Haemostasis</i> , 1999, 81, 660-661.	1.8	20
92	A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. <i>Clinical Chemistry</i> , 2000, 46, 1946-55.	1.5	20
93	Identification of smooth muscle-derived foam cells in the atherosclerotic plaque of human aorta with monoclonal antibody IIG10. <i>Tissue and Cell</i> , 1987, 19, 657-663.	1.0	19
94	Validation of Reference Genes for the Determination of Platelet Transcript Level in Healthy Individuals and in Patients with the History of Myocardial Infarction. <i>International Journal of Molecular Sciences</i> , 2013, 14, 3456-3466.	1.8	19
95	Comparison of a New P2Y ₁₂ Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy. <i>PLoS ONE</i> , 2013, 8, e69417.	1.1	19
96	Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. <i>Thrombosis Research</i> , 2014, 133, 811-816.	0.8	19
97	Platelet factor XIII becomes active without the release of activation peptide during platelet activation. <i>Thrombosis and Haemostasis</i> , 1993, 69, 282-5.	1.8	19
98	Factor XIII in bronchoalveolar lavage fluid from children with chronic bronchoalveolar inflammation. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1407-1413.	1.9	18
99	Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 822-832.	1.9	18
100	Platelet activating factor, the trigger of haemostatic alterations in rat anaphylaxis. <i>Clinical and Experimental Immunology</i> , 1977, 27, 512-5.	1.1	18
101	A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). <i>Thrombosis and Haemostasis</i> , 2000, 83, 268-73.	1.8	18
102	Association of vinculin to the platelet cytoskeleton during thrombin-induced aggregation. <i>Experimental Cell Research</i> , 1987, 168, 358-364.	1.2	17
103	Marker profile, enzyme activity, and function of a human myelomonocytic leukemia cell line. <i>Cellular Immunology</i> , 1992, 139, 531-540.	1.4	17
104	A collaborative study to establish the 1st International Standard for factor XIII plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1923-1929.	1.9	17
105	Molecular mechanism of the interaction between activated factor XIII and its glutamine donor peptide substrate. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 627-633.	1.9	17
106	Factor XIII B Subunit Polymorphisms and the Risk of Coronary Artery Disease. <i>International Journal of Molecular Sciences</i> , 2015, 16, 1143-1159.	1.8	17
107	Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	17
108	Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients. <i>Scientific Reports</i> , 2018, 8, 7662.	1.6	17

#	ARTICLE	IF	CITATIONS
109	Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. <i>Thrombosis and Haemostasis</i> , 2007, 97, 458-63.	1.8	17
110	A new mutation in the human pres gene and its effect on prestin function. <i>International Journal of Molecular Medicine</i> , 2007, 20, 545-50.	1.8	17
111	Î±2-Plasmin Inhibitor is a Substrate for Tissue Transglutaminase. <i>Thrombosis Research</i> , 2000, 99, 399-406.	0.8	16
112	How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?. <i>Platelets</i> , 2016, 27, 59-65.	1.1	16
113	Clinical and laboratory characteristics of antithrombin deficiencies: A large cohort study from a single diagnostic center. <i>Thrombosis Research</i> , 2017, 160, 119-128.	0.8	16
114	High-throughput scintillation proximity assay for transglutaminase activity measurement. <i>Analytical Biochemistry</i> , 2005, 343, 256-262.	1.1	15
115	Alloantibody developed in a factor XIII A subunit deficient patient during substitution therapy; characterization of the antibody. <i>Haemophilia</i> , 2016, 22, 268-275.	1.0	15
116	Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease. <i>Thrombosis Research</i> , 2008, 121, 469-476.	0.8	14
117	Factor XIII A subunit Val34Leu polymorphism in patients suffering atherothrombotic ischemic stroke. <i>Thrombosis Research</i> , 2010, 126, 159-162.	0.8	14
118	Expression of coagulation factor XIII subunit A in acute promyelocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 209-216.	0.7	14
119	Activation mechanism dependent surface exposure of cellular factor XIII on activated platelets and platelet microparticles. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1223-1235.	1.9	14
120	Cells containing Factor VIII subunit a in benign and soft tissue tumours. <i>Histopathology</i> , 1987, 11, 1341-1343.	1.6	13
121	Molecular characterization of p.Asp77Gly and the novel p.Ala163Val and p.Ala163Glu mutations causing protein C deficiency. <i>Thrombosis Research</i> , 2015, 135, 718-726.	0.8	13
122	Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A. <i>Thrombosis and Haemostasis</i> , 2006, 96, 176-82.	1.8	13
123	The frequency of the haemochromatosis C282Y mutation in the ethnic Hungarian and Romany populations of eastern Hungary. <i>British Journal of Haematology</i> , 1999, 107, 464-465.	1.2	12
124	Factor X Debrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency. <i>Haematologica</i> , 2008, 93, 299-302.	1.7	12
125	Activation and Consumption of Hageman Factor in the Anaphylactic Shock of the Rat. <i>International Archives of Allergy and Immunology</i> , 1976, 51, 496-507.	0.9	11
126	Localization of transglutaminase in human lenses.. <i>Journal of Histochemistry and Cytochemistry</i> , 1995, 43, 1173-1177.	1.3	11

#	ARTICLE	IF	CITATIONS
127	Assessment of thrombotic risk factors predisposing to thromboembolic complications in prosthetic orthopedic surgery. <i>Journal of Orthopaedic Science</i> , 2009, 14, 484-490.	0.5	11
128	Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency. <i>Thrombosis Research</i> , 2014, 133, 1158-1160.	0.8	11
129	Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause. <i>Annals of Hematology</i> , 2015, 94, 1301-1310.	0.8	11
130	Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism. <i>Thrombosis Research</i> , 2017, 158, 93-97.	0.8	11
131	Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients. <i>Molecular and Cellular Biochemistry</i> , 2018, 448, 199-209.	1.4	11
132	Kinetic determination of blood coagulation Factor XIII in plasma. <i>Clinical Chemistry</i> , 1985, 31, 35-40.	1.5	11
133	Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets. <i>Thrombosis and Haemostasis</i> , 1995, 73, 702-5.	1.8	11
134	Factor XIII subunits in human tears; their highly elevated levels following penetrating keratoplasty. <i>Clinica Chimica Acta</i> , 2011, 412, 271-276.	0.5	10
135	Assessment of Factor XIII. <i>Methods in Molecular Biology</i> , 2017, 1646, 277-293.	0.4	10
136	Covalent modification of platelet proteins by palmitate. <i>Blood</i> , 1989, 74, 1339-47.	0.6	10
137	Three novel mutations in the glycoprotein IIb gene in a patient with type II Glanzmann thrombasthenia. <i>Haematologica</i> , 2007, 92, 698-701.	1.7	9
138	A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears. <i>Journal of Immunological Methods</i> , 2010, 353, 87-92.	0.6	9
139	Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome. <i>Lupus</i> , 2010, 19, 1520-1526.	0.8	9
140	The lack of aspirin resistance in patients with coronary artery disease. <i>Journal of Translational Medicine</i> , 2016, 14, 74.	1.8	9
141	Deficiency causing mutations and common polymorphisms in the factor XIII-A gene. <i>Thrombosis and Haemostasis</i> , 2000, 84, 524-7.	1.8	9
142	The effect of methylglyoxal on actin. <i>Biochemical and Biophysical Research Communications</i> , 1981, 99, 617-622.	1.0	8
143	Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of α_2 -plasmin inhibitor to fibrin and its consequences on fibrinolysis. <i>Thrombosis Research</i> , 2012, 130, 528-534.	0.8	8
144	Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1797-806.	1.4	8

#	ARTICLE	IF	CITATIONS
145	Regulation of plasma factor XIII levels in healthy individuals; a major impact by subunit B intron K c.1952+144 C>G polymorphism. <i>Thrombosis Research</i> , 2016, 148, 101-106.	0.8	8
146	The factor XIII Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 885-894.	1.9	8
147	Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. <i>Thrombosis and Haemostasis</i> , 1996, 75, 161-7.	1.8	8
148	Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot. <i>Thrombosis and Haemostasis</i> , 2007, 98, 359-67.	1.8	8
149	A novel homozygous mutation (1619delC) in GPIIb gene associated with Glanzmann thrombasthenia, the decay of GPIIb-mRNA and the synthesis of a truncated GPIIb unable to form complex with GPIIIa. <i>Thrombosis and Haemostasis</i> , 2005, 93, 904-909.	1.8	7
150	Evaluation of flow cytometric HIT assays in relation to an IgG-specific immunoassay and clinical outcome. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 389-397.	0.7	7
151	Factor XIII: What does it look like?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 714-716.	1.9	7
152	N-glycosylation of blood coagulation factor XIII subunit B and its functional consequence. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1302-1309.	1.9	7
153	The identification of vimentin in human blood platelets. <i>European Journal of Cell Biology</i> , 1987, 43, 501-4.	1.6	7
154	Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting partial correct splicing of FXIII A-subunit mRNA. <i>Blood</i> , 1997, 89, 1279-87.	0.6	7
155	Evidence of Fibrinogen Degradation in Rat Anaphylaxis. <i>International Archives of Allergy and Immunology</i> , 1975, 49, 540-547.	0.9	6
156	Organization of the glycoprotein (GP) IIb/IIIa heterodimer on resting human platelets studied by flow cytometric energy transfer. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2001, 65, 47-58.	1.7	6
157	Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. <i>Thrombosis Research</i> , 2016, 139, 111-113.	0.8	6
158	Early onset of abdominal venous thrombosis in a newborn with homozygous type II heparin-binding site antithrombin deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 264-266.	0.5	6
159	A new ELISA method for the measurement of total t-PA-inhibitor level in human body fluids. <i>Journal of Immunological Methods</i> , 2019, 471, 27-33.	0.6	6
160	Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5963.	1.8	6
161	High frequency of factor V Leiden mutation and prothrombin 20210A variant in Romanies of Eastern Hungary. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1555-6.	1.8	6
162	The effect of glucose, glucose monophosphates and inorganic phosphate on the tryptic digestion of phosphorylase b. <i>Experientia</i> , 1970, 26, 25-26.	1.2	5

#	ARTICLE	IF	CITATIONS
163	Effect of prostaglandin I ₂ on platelet adhesion. <i>Biomaterials</i> , 1981, 2, 53-54.	5.7	5
164	Factor XIII deficiency: complete phenotypic characterization of two cases with novel causative mutations. <i>Haemophilia</i> , 2014, 20, 114-120.	1.0	5
165	The use of recombinant factor <sc>XIII</sc> in a major bleeding episode of a patient with congenital factor <sc>XIII</sc> deficiency – the first experience. <i>Haemophilia</i> , 2015, 21, e118-21.	1.0	5
166	Neutralizing autoantibody against factor XIII A subunit resulted in severe bleeding diathesis with a fatal outcome – characterization of the antibody. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1517-1520.	1.9	5
167	Terminal Phase Components of the Clotting Cascade in Patients with End-Stage Renal Disease Undergoing Hemodiafiltration or Hemodialysis Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8426.	1.8	5
168	THE EFFECT OF BORDETELLA PERTUSSIS VACCINE ON EPINEPHRINE INDUCED HYPERGLYCEMIA IN RATS. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1971, 26, 463-470.	2.7	4
169	Inhibition of platelet factor 3 availability by prostacyclin. <i>Prostaglandins</i> , 1980, 20, 935-945.	1.2	4
170	Von Willebrand Factor Antigen Latex Immunoassays are Affected to a Different Extent by Rheumatoid Factor. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 242-243.	0.7	4
171	Thrombomodulin-dependent effect of factor V Leiden mutation on factor XIII activation. <i>Thrombosis Research</i> , 2012, 129, 508-513.	0.8	4
172	Severe bleeding diatheses in an elderly patient with combined type autoantibody against factor <sc>XIII</sc> A subunit; novel approach to the diagnosis and classification of anti-factor XIII antibodies. <i>Haemophilia</i> , 2017, 23, 590-597.	1.0	4
173	Evaluation of endogenous thrombin potential among patients with antithrombin deficiency. <i>Thrombosis Research</i> , 2018, 166, 50-53.	0.8	4
174	Antithrombin Debrecen (p.Leu205Pro) – Clinical and molecular characterization of a novel mutation associated with severe thrombotic tendency. <i>Thrombosis Research</i> , 2017, 158, 1-7.	0.8	4
175	Monocytes of patients congenitally deficient in plasma factor XIII lack factor XIII subunit a antigen and transglutaminase activity. <i>Thrombosis and Haemostasis</i> , 1988, 59, 231-5.	1.8	4
176	Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. <i>Thrombosis and Haemostasis</i> , 1988, 60, 293-7.	1.8	4
177	Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins. <i>Thrombosis and Haemostasis</i> , 1997, 77, 1068-72.	1.8	4
178	A microassay to assess the oxidative resistance of low-density lipoproteins. <i>Clinical Chemistry</i> , 1998, 44, 1762-4.	1.5	4
179	DISTURBANCE OF BLOOD GLUCOSE REGULATION IN PERTUSSIS SENSITIZED RATS. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1972, 27, 257-263.	2.7	3
180	Subcellular distribution of vinculin in resting and activated platelets. <i>Thrombosis Research</i> , 1986, 41, 172.	0.8	3

#	ARTICLE	IF	CITATIONS
181	Factors of the extrinsic pathway of blood coagulation in tumour associated macrophages. <i>Thrombosis and Haemostasis</i> , 1989, 62, 850-5.	1.8	3
182	The effect of <i>Bordetella pertussis</i> vaccine on the histamine metabolism of rat tissues. <i>Acta Microbiologica Academiae Scientiarum Hungaricae</i> , 1969, 16, 211-8.	0.1	3
183	The effect of gold treatment on local Shwartzman phenomenon. <i>Acta Microbiologica Academiae Scientiarum Hungaricae</i> , 1968, 15, 331-6.	0.1	3
184	Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease. <i>Thrombosis and Haemostasis</i> , 2000, 84, 88-92.	1.8	3
185	Shwartzman phenomenon without endotoxin preparation. <i>Experientia</i> , 1969, 25, 1085-1086.	1.2	2
186	THE EFFECT OF ADRENALECTOMY ON PROTEASE SENSITIVITY AND ANAPHYLACTIC PROTEASE PRODUCTION IN THE RAT. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1971, 26, 308-314.	2.7	2
187	Inherited factor V deficiency associated with a novel heterozygous missense mutation (p.G493R) in a patient with excessive surgical bleeding. <i>Thrombosis and Haemostasis</i> , 2009, 102, 787-789.	1.8	2
188	First Step of the Transglutaminase Reaction Catalyzed by Activated Factor XIII Subunit A, Hybrid Quantum Chemistry/Molecular Mechanics Calculations. <i>Journal of Physical Chemistry B</i> , 2019, 123, 3887-3897.	1.2	2
189	Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1330-1334.	1.9	2
190	Effect of Î±2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism. <i>Thrombosis Research</i> , 2021, 203, 110-116.	0.8	2
191	An international collaborative study to assign value for Total Factor XIII Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 525-531.	1.9	2
192	The effect of <i>Bordetella pertussis</i> vaccine and adrenal hormones on 5-hydroxytryptamine level in rat tissues. <i>Acta Microbiologica Academiae Scientiarum Hungaricae</i> , 1970, 17, 63-8.	0.1	2
193	Covalent modification of platelet proteins by palmitate. <i>Blood</i> , 1989, 74, 1339-1347.	0.6	2
194	THE EFFECT OF BORDETELLA PERTUSSIS VACCINE ON PROTEASE SENSITIVITY AND ON THE ANAPHYLACTIC PROTEASE PRODUCTION IN RATS. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1972, 27, 55-62.	2.7	1
195	Effect of <i>Bordetella pertussis</i> vaccine on plasma corticosterone level and on ACTH-induced corticosterone secretion in rats. <i>Experientia</i> , 1973, 29, 112-113.	1.2	1
196	Changes of blood glucose during anaphylaxis in pertussis sensitized rats. <i>Experientia</i> , 1973, 29, 1411-1412.	1.2	1
197	Isolation and partial characterization of a cystine-rich basic heparin-binding protein from bovine platelets. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 70-76.	1.0	1
198	Possible role of factor XIII subunit A in FcÎ³; and complement receptor-mediated phagocytosis. <i>Cellular Immunology</i> , 2004, 228, 81-81.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Genetic Background of Inherited Factor XIII-A Subunit Deficiency: Review of the Literature and Description of Two New Cases. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 885-889.	1.5	1
200	High prevalence of factor V Leiden mutation and 20210A prothrombin variant in Hungary. <i>Thrombosis and Haemostasis</i> , 1999, 81, 660-1.	1.8	1
201	Inhibition of epinephrine-induced glycogen phosphorylase activation by <i>Bordetella pertussis</i> vaccine in rats. <i>Experientia</i> , 1973, 29, 219-220.	1.2	0
202	DISTURBANCE OF INSULIN RELEASE IN BORDETELLA PERTUSSIS VACCINATED RATS. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1973, 28, 138-144.	2.7	0
203	Procoagulant activity of thrombosthenin preparations. <i>Thrombosis Research</i> , 1977, 10, 635-644.	0.8	0
204	VINCULIN ISOFORMS IN HUMAN BLOOD PLATELETS. , 1987, 58, 1103.		0
205	European Thrombosis Research Organization Working Party on Factor XIII Abstracts of the 1st Meeting 2??4 September, 1992 Debrecen, Hungary. <i>Blood Coagulation and Fibrinolysis</i> , 1992, 3, 803.	0.5	0
206	The role of factor XIII in intratumoural fibrin formation. <i>Blood Coagulation and Fibrinolysis</i> , 1992, 3, 808.	0.5	0
207	Incompatibility of a recombinant thromboplastin and an APTT reagent on a fully automated coagulation analyzer. <i>Blood Coagulation and Fibrinolysis</i> , 1997, 8, 251-252.	0.5	0
208	The mystery of FXIII-A Val34Leu polymorphism. <i>Blood</i> , 2003, 101, 2904-2904.	0.6	0
209	Monitoring platelet function by PFA-100 closure time measurements during thrombolytic therapy of patients with myocardial infarction. <i>Thrombosis Research</i> , 2005, 116, 139-144.	0.8	0
210	Variant type Glanzmann thrombasthenia caused by homozygous p.724R>X mutation in β 3 integrin. <i>Thrombosis Research</i> , 2010, 125, 427-431.	0.8	0
211	FXIII levels in patients with systemic lupus erythematosus and antiphospholipid syndrome. <i>Clinica Chimica Acta</i> , 2019, 493, S416-S417.	0.5	0
212	Establishment of an International Registry of Patients with Inherited FXIII Deficiency.. <i>Blood</i> , 2007, 110, 2149-2149.	0.6	0
213	The Use of Recombinant FXIII in a Major Acute Bleeding Episode of a Patient with Congenital FXIII Deficiency â€” the First Experience. <i>Blood</i> , 2014, 124, 5065-5065.	0.6	0
214	PB2431 CAROTID INTIMAâ€”MEDIA THICKNESS PROGRESSION AND BLOOD COAGULATION FACTOR XIII LEVELS IN TYPE 2 DIABETES: 8 YEARS OF FOLLOWâ€”UP. <i>HemaSphere</i> , 2019, 3, 1077.	1.2	0
215	Pathomechanism of the side-effects of hydralazine. <i>Acta Medica Academiae Scientiarum Hungaricae</i> , 1969, 26, 357-62.	0.1	0
216	Effect of adrenalectomy and cortisone treatment of 5-hydroxytryptophane decarboxylase and monoamine-oxidase activity of rat tissue. <i>Acta Physiologica Academiae Scientiarum Hungaricae</i> , 1972, 42, 327-31.	0.0	0

#	ARTICLE	IF	CITATIONS
217	Effect of cortisone treatment and adrenalectomy on histamine metabolism in rat tissue. <i>Acta Physiologica Academiae Scientiarum Hungaricae</i> , 1969, 36, 67-72.	0.0	0
218	The Effect of Activated FXIII, a Transglutaminase, on Vascular Smooth Muscle Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5845.	1.8	0